{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=92",
    "query": {
      "condition": "Safety Study",
      "page": 92
    },
    "page_size": 10
  },
  "pagination": {
    "page": 92,
    "page_size": 10,
    "total_count": 33600,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=93&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=91&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T21:22:44.835Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01811576",
      "title": "Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Growth Hormone Deficiency"
      ],
      "interventions": [
        {
          "name": "TV-1106",
          "type": "DRUG"
        },
        {
          "name": "Recombinant human growth hormone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "23 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "23 Years to 65 Years"
      },
      "enrollment_count": 52,
      "start_date": "2013-03-31",
      "completion_date": "2013-08-05",
      "has_results": false,
      "last_update_posted_date": "2021-12-10",
      "last_synced_at": "2026-11-21T21:22:44.835Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01811576"
    },
    {
      "nct_id": "NCT02974868",
      "title": "Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "PF-06651600",
          "type": "DRUG"
        },
        {
          "name": "PF-06700841",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 142,
      "start_date": "2016-12-15",
      "completion_date": "2019-05-15",
      "has_results": true,
      "last_update_posted_date": "2020-05-26",
      "last_synced_at": "2026-11-21T21:22:44.835Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Santa Ana, California • Santa Monica, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02974868"
    },
    {
      "nct_id": "NCT00565591",
      "title": "Study Mild Intermittent Asthma to Assess the Topical Safety and Tolerability of Albuterol Sulfate Acu-30™ DPI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allergic Asthma"
      ],
      "interventions": [
        {
          "name": "Albuterol sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Respirics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2007-11",
      "completion_date": "2008-02",
      "has_results": false,
      "last_update_posted_date": "2008-02-15",
      "last_synced_at": "2026-11-21T21:22:44.835Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00565591"
    },
    {
      "nct_id": "NCT06685718",
      "title": "A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Lung Cancer",
        "NSCLC",
        "NSCLC (Non-small Cell Lung Carcinoma)",
        "EGFR Activating Mutation",
        "EGFR Mutation-Related Tumors"
      ],
      "interventions": [
        {
          "name": "BG-60366",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeOne Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2024-12-05",
      "completion_date": "2026-04-21",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-21T21:22:44.835Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06685718"
    },
    {
      "nct_id": "NCT06834360",
      "title": "A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Rhinosinusitis With Nasal Polyps"
      ],
      "interventions": [
        {
          "name": "Itepekimab (SAR440340)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Mometasone furoate nasal spray (MFNS)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2025-02-06",
      "completion_date": "2027-02-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-21T21:22:44.835Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Napa",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06834360"
    },
    {
      "nct_id": "NCT05856760",
      "title": "A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A Nephropathy"
      ],
      "interventions": [
        {
          "name": "Sparsentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Travere Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2023-05-19",
      "completion_date": "2024-10-25",
      "has_results": true,
      "last_update_posted_date": "2025-11-20",
      "last_synced_at": "2026-11-21T21:22:44.835Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Chula Vista, California • Garden Grove, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05856760"
    },
    {
      "nct_id": "NCT05076149",
      "title": "A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "VX-121/TEZ/D-IVA",
          "type": "DRUG"
        },
        {
          "name": "ELX/TEZ/IVA",
          "type": "DRUG"
        },
        {
          "name": "IVA",
          "type": "DRUG"
        },
        {
          "name": "Placebo (matched to VX-121/TEZ/D-IVA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (matched to ELX/TEZ/IVA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (matched to IVA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 597,
      "start_date": "2021-10-27",
      "completion_date": "2023-11-30",
      "has_results": true,
      "last_update_posted_date": "2024-06-13",
      "last_synced_at": "2026-11-21T21:22:44.835Z",
      "location_count": 62,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 55 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05076149"
    },
    {
      "nct_id": "NCT02061358",
      "title": "Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Viral Infection"
      ],
      "interventions": [
        {
          "name": "UV-4B 3 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 10 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 30 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 90 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 180 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 360 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 720 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 64,
      "start_date": "2014-07",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-11-21T21:22:44.835Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02061358"
    },
    {
      "nct_id": "NCT03926026",
      "title": "Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Blepharitis"
      ],
      "interventions": [
        {
          "name": "Fluticasone Propionate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicox Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2019-03-18",
      "completion_date": "2019-10-21",
      "has_results": true,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-11-21T21:22:44.835Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03926026"
    },
    {
      "nct_id": "NCT05040178",
      "title": "An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hyperammonemia",
        "Methylmalonic Acidemia",
        "Propionic Acidemia"
      ],
      "interventions": [
        {
          "name": "Carglumic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RECORDATI GROUP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 20,
      "start_date": "2022-06-30",
      "completion_date": "2032-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-04-15",
      "last_synced_at": "2026-11-21T21:22:44.835Z",
      "location_count": 5,
      "location_summary": "Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05040178"
    }
  ]
}